J. V. van Giezen

发表

Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model

M. Penn, Mazen K. Khalil, Dominik M. Wiktor, 2010, Thrombosis and Haemostasis.

Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.

Jonas Boström, P. Bach, M. O'Sullivan, 2013, European journal of medicinal chemistry.

Stabilizing Role of Platelet P2Y12 Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques

M. O. oude Egbrink, R. Storey, J. Heemskerk, 2010, PloS one.

Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

J. Sidaway, J. Björkman, J. V. van Giezen, 2012, Journal of cardiovascular pharmacology and therapeutics.

Evaluation of platelet function, a method comparison

T. Lindahl, S. Nylander, J. V. van Giezen, 2006, Platelets.

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.

H. Zachrisson, J. Björkman, J. V. van Giezen, 2009, Thrombosis research.

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

J. V. van Giezen, B. Emanuelsson, J. Weilitz, 2012, Thrombosis research.

Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.

H. Zachrisson, F. Giordanetto, J. Björkman, 2013, Journal of medicinal chemistry.

A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.

Jonas Boström, P. Bach, K. Brickmann, 2011, Bioorganic & medicinal chemistry letters.

Retinoic Acid Enhances Fibrinolytic Activity In-Vivo by Enhancing Tissue Type Plasminogen Activator (t-PA) Activity and Inhibits Venous Thrombosis

B. Bouma, G. Boon, J. V. van Giezen, 1993, Thrombosis and Haemostasis.

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication

H. Crijns, J. Heemskerk, Y. Henskens, 2015, Haematologica.

The Fab-fragment of a PAI-1 Inhibiting Antibody Reduces Thrombus Size and Restores Blood Flow in a Rat Model of Arterial Thrombosis

V. Nerme, J. V. van Giezen, T. Abrahamsson, 1997, Thrombosis and Haemostasis.

Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists

R. G. Humphries, J. V. van Giezen, J. V. Giezen, 2005, Seminars in thrombosis and hemostasis.

Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y12 antagonist ticagrelor

M. O. oude Egbrink, J. Heemskerk, R. Megens, 2011, Thrombosis and Haemostasis.

Cross‐linking of &agr;2‐antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences

B. Bouma, J. V. van Giezen, J. Jansen, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

PAI-1 inhibition enhances the lysis of the platelet-rich part of arterial-like thrombi formed in vitro. A comparative study using thrombi prepared from rat and human blood.

V. Nerme, J. V. van Giezen, T. Abrahamsson, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis

B. Bouma, G. H. Dreteler, J. V. van Giezen, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Reply: To PMID 23312702.

G. Brandrup-Wognsen, L. Gan, H. Emanuelsson, 2013, Journal of the American College of Cardiology.

Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.

H. Zachrisson, F. Giordanetto, J. Björkman, 2014, Bioorganic & medicinal chemistry letters.

Fibrinolytic Activity in Blood Is Distributed over a Cellular and the Plasma Fraction which Can Be Modulated Separately

B. Bouma, J. V. van Giezen, J. Jansen, 1994, Thrombosis and Haemostasis.

Inhibition of Fibrinolytic Activity In-Vivo by Dexamethasone Is Counterbalanced by an Inhibition of Platelet Aggregation

J. V. van Giezen, J. Jansen, J., 1992, Thrombosis and Haemostasis.

Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI

Daniel F. Freitag, A. Khera, P. Ellinor, 2019, Stroke.

Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation

F. Giordanetto, P. Greasley, J. V. van Giezen, 2009, Journal of thrombosis and haemostasis : JTH.

Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist

S. Husted, J. V. van Giezen, 2009, Cardiovascular therapeutics.

Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1

J. Sidaway, D. Armstrong, L. Ewart, 2014, Journal of cardiovascular pharmacology and therapeutics.

Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist

S. Husted, J. V. van Giezen, 2009, Cardiovascular therapeutics.